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ABSTRACT 
 
The adenosine 2A receptor (A2AR), a G-protein-coupled receptor (GPCR), was 
solubilised and purified encapsulated in styrene maleic acid lipid particles (SMALPs). 
The purified A2AR-SMALP was associated with phospholipids characteristic of the 
plasma membrane of Pichia pastoris, the host used for its expression, confirming that 
the A2AR-SMALP encapsulated native lipids. The fluorescence spectrum of the A2AR-
SMALP showed a characteristic broad emission peak at 330 nm, produced by 
endogenous Trp residues. The inverse agonist ZM241385 caused 30% increase in 
fluorescence emission, unusually accompanied by a red-shift in the emission 
wavelength. The emission spectrum also showed sub-peaks at 321 nm, 335 nm and 
350 nm, indicating that individual Trp inhabited different environments following 
ZM241385 addition. There was no effect of the agonist NECA on the A2AR-SMALP 
fluorescence spectrum. Substitution of two Trp residues by Tyr suggested that 
ZM241385 affected the environment and mobility of Trp2466.48 in TM6 and Trp2687.33 
at the extracellular face of TM7, causing transition to a more hydrophobic environment. 
The fluorescent moiety IAEDANS was site-specifically introduced at the intracellular 
end of TM6 (residue 2316.33) to report on the dynamic cytoplasmic face of the A2AR. 
The inverse agonist ZM241385 caused a concentration-dependent increase in 
fluorescence emission as the IAEDANS moved to a more hydrophobic environment, 
consistent with closing the G-protein binding crevice. NECA generated only 30% of 
the effect of ZM241385. This study provides insight into the SMALP environment; 
encapsulation supported constitutive activity of the A2AR and ZM241385-induced 
conformational transitions but the agonist NECA generated only small effects.    
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Abbreviations:  A2AR, adenosine A2A receptor; DMPC, 1,2-dimyristoyl-sn-glycero-3-
phosphocholine; ECL, extracellular loop; GPCR, G-protein-coupled receptor; 
IAEDANS, 5-({2-[(iodoacetyl)amino]ethyl}amino)naphthalene-1-sulfonic acid;  ICL, 
intracellular loop; LC-MS/MS, liquid chromatography with tandem mass spectrometry; 
m/z, mass to charge ratio; PC, phosphatidycholine; PE, phosphatidylethanolamine; 
PG, phosphatidyglycerol; PS, phosphatidylserine; SMA, styrene maleic acid; SMALP, 
styrene maleic acid lipid particle; ZM241385, {4-(2-[7-amino-2-(2-
furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5yl amino]ethyl)phenol}.  
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1. Introduction 
G-protein-coupled receptors (GPCRs) are the largest class of membrane proteins in 
the human genome (with >800 receptors) and are central to drug discovery programs 
as they are the therapeutic target for 30-40% of clinically-prescribed drugs [1]. They 
share a common architecture comprising a bundle of seven transmembrane helices 
(TMs) [2]. The structural biology of GPCRs is now well established, with crystal 
structures for more than 50 different GPCRs currently deposited and over 250 of their 
complexes with different ligands [3]. This structural information is now being enhanced 
further by cryo-EM structures of GPCR complexes [4,5]. This extensive structural 
information has highlighted that GPCRs are highly dynamic proteins and that the 
receptor conformation is dictated by the structure and efficacy of the bound ligand (full 
agonist, partial agonist, antagonist or inverse agonist – which inhibits basal signalling). 
This spectrum of conformations allows these receptors to couple to multiple effectors 
[6] and for responses to be ‘tuned’, up or down, by allosteric modulators that bind to 
sites discrete from the orthosteric site used by the natural agonist [7]. This structural 
knowledge-base has facilitated an understanding of the conserved conformational 
changes that underpin GPCR activation in general [8]. Nevertheless, it is now 
recognised that approaches are required that progress beyond static structures to a 
dynamic understanding. Although solution-based NMR spectroscopy of GPCRs in 
detergent micelles is starting to address aspects of this [9], it is acknowledged that 
GPCRs need to be studied in an environment closer to their physiological context 
within the lipid bilayer of a cell membrane. This is particularly important for 
investigating GPCRs as they are regulated by the juxtaposition of specific membrane 
lipids [10-12].  
In recent years there has been a growing interest in the use of membrane mimetic systems 
for studying membrane proteins. The use of poly(styrene-co-maleic acid) (SMA) has 
increasingly been adopted as a strategy for extracting a nanoscale disc of native cell 
membrane bilayer encapsulated by the SMA polymer, referred to as SMA lipid particle 
(SMALP) [13-16]. SMA has its limitations in some downstream biological applications. 
In particular, SMALPs have been shown to be unstable in the presence of divalent 
cations such as Mg2+, with precipitation of the polymer evident at 5 mM Mg2+. SMA is 
also pH sensitive. In an acidic environment (pH values <5.8), the maleic acid groups 
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become protonated causing the polymer to precipitate. This limits the SMALP 
approach to proteins that function at neutral or basic pHs. Nevertheless, SMALPs have 
attracted considerable interest for purifying membrane proteins including GPCRs [17]. 
We reported the first purification of an active GPCR, in the complete absence of 
detergent at any stage using the SMALP approach [18-19]; other GPCRs have 
subsequently been solubilised [20]. The first GPCR-SMALP purified was the the 
adenosine A2A receptor (A2AR). This is a typical GPCR with a well-defined 
pharmacology. It belongs to a family of four GPCRs (A1R, A2AR, A2BR, A3R) that 
mediate the actions of adenosine and are attractive drug targets [21]. The A2AR 
regulates blood flow to cardiac muscle and regulates the release of the 
neurotransmitters dopamine and glutamate in the brain, and is well-known as the 
target for caffeine, which blocks this receptor [22]. It is noteworthy that the A2AR has 
been shown to possess basal activity in the absence of agonist stimulation, referred 
to as constitutive activity [23]. This receptor is a good choice as a model receptor to 
investigate the structure/function of a GPCR as there is a wealth of structural 
information for the A2AR with over 40 structures deposited in the Protein Data Bank as 
listed in the GPCRdb [3]. This includes the conformation of the A2AR bound to ligands 
of different efficacy (full agonist, partial agonist, antagonist, inverse agonist) with 
corresponding structures of fully active, partially active and inactive, receptor 
conformations [24]. 
 
In this study we investigate ligand-induced conformational changes to the A2AR 
encapsulated in a SMALP using a combination of fluorescence from endogenous Trp 
residues plus fluorescence from an introduced reporter (IAEDANS) positioned in a 
dynamic part of the receptor structure, at the cytoplasmic end of TM6. We establish 
that the A2AR adopted at least a partially active conformation in the SMALP and was 
able to undergo ligand-induced conformational change in response to binding the 
inverse agonist ZM241385. In contrast, the SMALP-encapsulated A2AR exhibited little 
conformational change in response to the full agonist NECA. This has ramifications 
for using GPCR-SMALPs as a platform for studying GPCRs. 
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2.  Materials and methods 
 
2.1 Materials 
 
SMA2000 anhydride was from Cray Valley (UK). ZM241385 {4-(2-[7-amino-2-(2-
furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5yl amino]ethyl)phenol} was purchased from 
Tocris, The mutant constructs [W246Y]A2AR and [W268Y]A2AR were custom 
synthesised and cloned into the EcoRI-NotI sites of the vector pPICZαA by Genscript.  
 
2.2. Human A2AR Expression 
 
An N-terminal His-tagged A2AR was expressed in Pichia pastoris as described 
previously [18]. The receptor sequence terminated at Ala316 (Fig. S1) as this construct 
is degradation resistant [25] and has been used extensively in structural studies, 
having wild-type pharmacology [26-27]. Prior to SMA-extraction, cells were disrupted 
following suspension in breaking buffer (50 mM sodium–phosphate buffer, 100 mM 
NaCl, 5% glycerol, EDTA-free protease inhibitor, pH 7.5, 4 C) by 3-5 passes using an 
Avestin Emulsiflex C3 cell-disrupter. Unbroken cells and debris were removed by 
centrifugation (5000 x g, 10 min, 4 °C). The A2AR-expressing membrane fraction was 
then sedimented (100,000 x g, 60 min, 4 °C) and re-suspended to 80 mg mL-1 (wet 
weight) in extraction buffer (300 mM NaCl, 20 mM HEPES, pH 7.5). Membranes were 
stored at -80 °C until needed. 
 
2.3. Generation of A2AR-SMALPs 
 
SMA was prepared from SMA anhydride and used to solubilise A2AR from membranes 
as described previously [16,18]. Briefly, A2AR-expressing membrane preparations 
were thawed on ice, and an equal volume of 2 x SMA buffer (5% w/v SMA, 300 mM 
NaCl, 20 mM HEPES, EDTA-free protease inhibitor, pH 7.5) added to yield a final 
concentration of 40 mg mL-1 (wet weight) in 2.5 % (w/v) SMA. Following gentle 
agitation for 1 h at room temperature, non-solubilised material was removed by 
centrifugation (100,000 x g, 60 min, 4°C) to yield a supernatant containing A2AR–
SMALPs. 
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2.4. Purification of A2AR-SMALPs 
 
All purification steps were carried out at 4 °C. The A2AR–SMALP supernatant was 
incubated with ~1 mL Ni2+-NTA resin, overnight on an end-over-end rotator. The 
column was washed with 20 column volumes (cv) of wash buffer (300 mM NaCl, 20 
mM HEPES, 25 mM imidazole, EDTA-free protease inhibitor pH 7.5). Elution of A2AR–
SMALP was achieved with 10 cv of elution buffer (300 mM NaCl, 20 mM HEPES, 250 
mM imidazole, EDTA-free protease inhibitor pH 7.5). Elution fractions were pooled, 
buffer-exchanged into assay buffer (300 mM NaCl, 20 mM HEPES, pH 7.5) and 
concentrated using spin-concentrators (10 kDa cut-off). Concentrations of purified 
A2AR-SMALP were determined using SDS-PAGE and densiometric analysis against 
protein standards in ImageJ. Final concentrations ranged between 0.2–1 mg ml-1. 
 
2.5. IAEDANS labelling 
 
Ala2316.33 of the A2AR was mutated to Cys using the QuikChange site-directed 
mutagenesis kit (Stratagene, Cambridge, UK) according to the manufacturer’s 
instructions.  The oligonucleotide primers 5’-G-AAA-GAG-GTT-CAC-TGT-GCT-AAG-
TCC-TTG-3’ (sense) and 5’-CAA-GGA-CTT-AGC-ACA-GTG-AAC-CTC-TTT-C-3’ 
(antisense) were used, with appropriate base changes shown in bold. All receptor 
constructs were confirmed by automated fluorescent sequencing. For labelling by 
IAEDANS (5-({2-[(iodoacetyl)amino]ethyl}amino)naphthalene-1-sulfonic acid), 0.05 
mg of [A231C]A2AR-SMALP in phosphate buffer (50 mM NaH2PO4, 300 mM NaCl, 
pH8.0) was added to 3 µl of 5 mM IAEDANS in DMSO (10-fold excess of IAEDANS) 
in a total reaction volume of 100 µl and incubated for 3 h at 20 °C with gentle rotation. 
Samples were then prepared using a Vivaspin 500 centrifugal concentrator (10,000 
MWCO; 15,000 x g, 2 min), washed with 3 x 200 µl phosphate buffer then centrifuged 
as above to reduce sample volume to 100 µl. Labelling of ‘empty SMALPs’ (DMPC-
SMALPs) containing the lipid DMPC but lacking A2AR was performed using the same 
protocol. 
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2.6. Fluorescence measurements 
 
Fluorescence measurements were made using a PTI QuantaMaster 300 fluorimeter 
using continuous Xe arc excitation. Samples were contained in a 0.3 cm quartz 
fluorescence cuvette (Starna Scientific). Emission spectra were obtained by exciting 
the protein at 295 nm and 340 nm for tryptophan and IAEDANS respectively. 
Excitation slit widths of 0.2 mm (± 0.8 nm)  and emission slit widths of 0.8 mm (± 3.2 
nm) were used for all measurements with a scan speed of 500 nm/min. Emission 
spectra were measured between 300 - 400 nm for tryptophan fluorescence 
experiments and 425 - 625 nm for IAEDANS. For determination of Stern-Volmer 
constants, acrylamide was titrated into the cuvette up to a final concentration of 2 M. 
At each titration point the emission intensity of the tryptophan was measured. The 
resulting intensity data were adjusted to take into account the effect of diluting the 
A2AR-SMALP, then plotted to provide a Stern-Volmer constant using the equation F0/F-
1 = 1 +q0[Q], where F0  is the intensity of fluorescence in the absence of quencher, F-
1 is the intensity with the quencher, present at concentration [Q], 0 is the lifetime of 
the excited state and q is the Stern-Volmer constant. 
 
2.7 Lipid extraction 
 
Total lipid was extracted from P. pastoris cells using the method described by Spickett 
et al. 2001 [28]. Shake flask cultures of 25 mL were set up and approximately 5 mL 
culture harvested 48 h post-induction. The culture was centrifuged at 10,000 x g and 
the supernatant discarded. The cell pellets weighed approximately 50 mg and 0.5 mL 
methanol at 50 °C was added before incubating in a sonicating water bath for 15 min. 
0.5 mL chloroform was then added and the cells sonicated for a further 15 min. 0.5 mL 
of 0.88% KCl was added and the mixture was vortexed. The cells were centrifuged at 
10,000 x g for 2 min to separate the organic and aqueous layers. The organic (lower) 
layer was transferred to a fresh tube and dried under a stream of nitrogen gas. The 
lipid extracts were stored at -80°C until analysis.  For lipid extraction from A2AR–
SMALPs, approximately 50 mL of cell culture was used, and the resulting A2AR–
SMALP preparation after purification according to section 2.4 was subjected to 
methanol-chloroform extraction as described above for total lipids. 
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2.8 Liquid chromatography with tandem mass spectrometry (LC-MS/MS) 
 
Phospholipid extracts of Pichia pastoris membranes were reconstituted in 200 µl 1:1 
methanol: chloroform (v/v) and diluted (typically 1/1000) in 20% isopropyl alcohol in 
acetonitrile. Aliquots (10 µL) were injected via an autosampler onto a ACE 3-SIL HILIC 
column (150 x 3.1mm, Hichrom, UK) and separated using a U3000 HPLC system 
controlled by Chromeleon software (ThermoFisher, Hemel Hempstead, UK). The 
HPLC was interfaced to a 5600 TripleTOF mass spectrometer (ABSciex, Warrington, 
UK) via a TurboSpray® ion source. Elution was achieved by a multi-step gradient as 
follows: 0-1 min held at 5% B; 1-5 mins to 8% B; 5-10 min to 15% B; 10-13 mins held 
at 15% B; 13-23 mins to 35% B; 23-28 mins held at 35% B; 28-29 mins to 5% B; 29-
45 mins held at 5% B, where solvent A was 20% isopropyl alcohol in acetonitrile and 
solvent B was 20% isopropyl alcohol in 20 mM aqueous ammonium formate.  The flow 
rate was set to 300 μl/min throughout. The source temperature was set at 350 oC; the 
spray voltage was 5500V; the declustering potential was set to 50 V for all scans; 
nitrogen was used as the curtain gas and nebulising gas with flow rates set to 35 AU 
and 26 AU respectively. Survey scan MS data were acquired by electrospray 
ionization in positive mode from 400-1200 Da in high resolution mode for 500 ms. 
Information dependent data acquisition (IDA) was used to collect MS/MS data based 
on following criteria: the 4 most intense ions with +1 charge and a minimum intensity 
of 250 cps were chosen for analysis, using dynamic exclusion for 20 sec after 2 
occurrences and a fixed collision energy setting of 47 eV. 
 
2.9 Molecular modelling 
 
Models of [W246Y]A2AR and [W268Y]A2AR were built in Modeller [29] using the A2AR 
with bound ZM241385 (PDB ID: 3EML) as a template. 1000 models were generated 
for each mutation and scored using the Modeller objective scoring function. The best 
models were subsequently relaxed using Rosetta [30]. Ligands were docked and 
scored using PLANTS under the default settings [31]. 
 
2.10 Residue numbering  
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 The Ballesteros-Weinstein nomenclature system for family A GPCR residues is 
employed throughout this article, indicated by a superscript number [32]. This provides 
the unique position of each residue with two numbers; its transmembrane helix plus 
its position relative to the most conserved residue (ascribed the number 50) in that 
helix across all family A GPCRs. This numbering system allows direct comparison of 
residues between different GPCRs.  
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3. Results 
 
3.1. Tryptophan fluorescence of A2AR-SMALP 
  
The A2AR-SMALPs were generated using SMA (2.5% w/v) to extract the receptors 
from A2AR-expressing membranes into SMALPs, followed by purification of the A2AR-
SMALPs as previously described [18]. Each sample of purified A2AR-SMALP was 
tested for specific binding of the A2AR radio-ligand [3H]ZM241385 to ensure that it was 
pharmacologically active. The wild-type A2AR has seven tryptophan residues but the 
C-terminally truncated construct used in the current study has only six (Supplentary 
Fig. 1a).   Of these, Trp291.55 and Trp321.58 are at the bottom of TM1, at the junction 
with the first intracellular loop (ICL1). Trp1294.50 is in TM4. Trp1434.64 is at the junction 
between TM4 and extracellular loop 2 (ECL2), Trp2466.48 is in TM6 and Trp2687.33 is 
at the extracellular face of TM7 at the junction with ECL3 (Fig. 1).  
 
 
 
Fig. 1. Location of the Trp residues in the A2AR. 
The structure of ZM241385 (inverse agonist)-bound A2AR (yellow; PDB ID: 3EML) is 
aligned to the structure of the NECA (agonist)-bound A2AR (red; PDB ID: 2YDV ) with 
the Trp residues indicated, viewed through the plane of the membrane (panel a) and 
from above (panel b). 
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The initial stage of the investigation was to determine the Trp fluorescence spectrum 
of the apo A2AR-SMALP, in the absence of any ligand (Fig. 2). The spectrum exhibited 
a broad peak (reflecting the multiple Trp in the receptor) with a maximum of ~330 nm, 
indicating that the Trp residues are located in relatively non-polar environments. This 
is consistent with the buried positions of the Trp residues within the receptor structure, 
as seen in the crystal structures of the receptor (Fig.1). The fluorescence of ZM241385 
at 330 nm is 2550 AU, less than 1.5% of that of the receptor, indicating that the 
changes seen in Fig. 2 are due to the A2AR. We also determined the fluorescence 
spectrum of the A2AR after solubilisation with the detergent n-dodecyl--D-
maltopyranoside (data not shown); it also had a single peak at approximately 330 nm, 
suggesting that the overall folding of the protein was similar in the SMALP and 
detergent. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Fluorescence of A2AR-SMALP. 
Fluorescence spectrum in the absence (A2AR-SMALP) and presence (ZM:A2AR-
SMALP) of ZM241385 (1 M). 
 
 
 
3.2. Ligand-induced changes in tryptophan fluorescence 
 
To investigate the effect on the Trp fluorescence spectrum of ligands binding to the 
A2AR encapsulated in a SMALP, two ligands possessing different pharmacological 
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properties (efficacy) were employed; i) ZM241385, an A2AR-selective inverse agonist 
which suppresses receptor activation [25] and ii) NECA, an agonist that fully activates 
the receptor. Binding of ZM241385 increased the Trp fluorescence A2AR-SMALP 
markedly (30%) compared to the unoccupied receptor (Fig. 2). In contrast there was 
no change in the fluorescence with NECA (data not shown). The 30% increase in the 
Trp fluorescence of the ZM241385:A2AR-SMALP complex compared to the apo A2AR 
reveals a ZM241385-induced conformational change in the receptor structure upon 
ligand binding. Intriguingly, the increase in fluorescence intensity was accompanied 
by a red shift. This is unusual as it would be expected that an increase in intensity 
(interpreted as a movement of Trp residues into a less polar environment) should be 
accompanied by a corresponding blue shift. However, close examination of the 
spectrum of the ZM241385-bound conformation offers some insight. The apo A2AR-
SMALP spectrum shows only a single broad peak at 330 nm indicating that the Trp 
residues are either in similar environments or that their peaks are broad and overlap 
to a large degree. It can be seen in Fig. 2, that ZM241385 binding induced the single 
peak to resolve into three clear sub-peaks at approximately 321 nm, 335 nm and 350 
nm. These peaks are likely to represent individual Trp residues affected by the change 
in local structure induced by ZM241385 binding, resulting in a significant change in 
their spectral characteristics. It is therefore possible that the unusual redshift observed 
upon ZM241385 binding is the net result of complex changes in the fluorescence 
arising from multiple Trp transitions in the protein. 
 
3.3. Changes in Trp fluorescence correlate with ZM241385 binding to A2AR-SMALP 
 
The concentration-dependence of changes in the Trp fluorescence observed when 
ZM241385 bound was determined. The effect of ZM241385 binding on the overall Trp 
fluorescence is presented in Fig. 3a. This exhibits a pEC50  = 7.2 ± 0.22 (n = 3) which 
is comparable to the corresponding value for ZM241385 binding to A2AR-SMALP (7.79 
± 0.14, n = 3) and binding to A2AR in whole membranes (7.95 ± 0.45, n = 3). As the 
fluorescence spectrum of the ZM241385-bound state exhibited three distinct sub-
peaks of fluorescence (at 321 nm, 335 nm and 350 nm), the response of each of these 
to increasing concentrations of ZM241385 was analysed. The ZM241385 
concentration-response curves at 321 nm, 335 nm and 350 nm gave similar pEC50 
values of 6.93 ± 0.14, 7.00 ± 0.10 and 7.01 ± 0.10 respectively (Fig 3b). This indicates 
13 
 
that each of the putative Trp residues that correspond to these peaks are responding 
to the same binding event.  
 
 
 
 
Fig.3. ZM241385-induced changes in fluorescence of A2AR-SMALP. 
Panel a; the dose-dependent effect of ZM241385 binding on the overall fluorescence. 
Panel b; the dose-dependent effect of ZM241385 binding on the individual 
fluorescence peaks at 321 nm, 335 nm and 350 nm. 
 
3.4. Solvent accessibility of Trp residues in apo and ligand-bound states. 
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Stern-Volmer (SV) quenching experiments were performed to compare the solvent 
accessibility of the Trp residues in the unoccupied apo A2AR-SMALP versus the 
ZM241385-bound state. Acrylamide was used as the fluorescence quenching agent, 
as it has the advantage of being uncharged thereby avoiding any potential charge-
related problems with the polymer component of the SMALP. A full emission spectrum 
was determined at each acrylamide concentration, so that an SV constant could be 
calculated for the overall fluorescent species (by producing an SV curve from an 
average of all data). In addition, SV constants were also calculated for each of the Trp 
peaks (321 nm, 335 nm, 350 nm) resolved in the ZM241385-bound state (Fig. 4a). In 
all cases, the binding of ZM241385 to the A2AR-SMALP decreased the SV constant 
(Fig. 4b), indicating that the solvent accessibility of the Trp residues in the apo A2AR 
decreased upon ZM241385 binding. This agrees well with our earlier observation that 
the overall fluorescence intensity of the A2AR-SMALP increased when ZM241385 
occupied the receptor (Fig. 2), indicating that the Trp residues moved to a less polar 
environment. 
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Fig. 4. Stern-Volmer quenching data. 
Upper panel; quenching data for A2AR-SMALP and ZM:A2AR-SMALP. Lower panel; 
calculated SV constants for overall fluorescence and for individual sub-peaks. 
 
Interestingly, there was a difference between the SV constants calculated at different 
positions in the spectrum (corresponding to the three peaks observed in the 
ZM241385-bound state. Fig. 4b). The SV constants for 335 nm and 350 nm were very 
similar (3.04 and 3.16 respectively), suggesting that Trp residues generating these 
peaks have similar solvent accessibilities. In contrast, the 321 nm peak has a much 
lower SV value (SV = 2.60) indicating a decreased solvent exposure compared to 335 
 
 
SMALP 
Sample 
Wavelength 
(nm) 
SV constant 
(M-1) 
Apo A2AR overall 3.31 
 321 3.36 
 335 3.83 
 350 3.85 
ZM:A2AR overall 2.60 
 321 2.60 
 335 3.04 
 350 3.16 
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nm and 350 nm. This latter result correlates well with the blue-shifted nature of the 
321 nm peak. 
 
3.5. Measurement of fluorescence anisotropy changes upon ZM241385 binding 
 
Fluorescence anisotropy can be used to determine changes in fluorophore flexibility. 
Depending upon the fluorescence lifetime of the fluorophore, this can include detecting 
changes in the tumbling time of the assembly in solution, as well as changes in the 
motions of the fluorophore within the context of the assembly. We have already shown 
in this study that the binding of ZM241385 to the A2AR-SMALP altered the environment 
and solvent accessibility of one or more of the Trp residues. It is also likely that 
ZM241385 binding altered the steric freedom of these residues in the receptor. It is 
however, unlikely that the overall tumbling of the A2AR-SMALP would be affected 
significantly by ZM241385 binding to the SMALP-encapsulated A2AR. 
Measurements of the fluorescence anisotropy of A2AR-SMALP showed that 
binding of ZM241385 produced a clear increase in anisotropy (apo A2AR-SMALP, 
0.1044 ± 0.0027; ZM241385-bound A2AR-SMALP, 0.1341 ± 0.0020, values are mean 
± s.e.m., n = 3, p<0.001). This indicated that the Trp residues are less mobile in the 
ZM241385:A2AR-SMALP complex than in the unoccupied apo A2AR-SMALP. Again, 
this agrees well with other data in this study (Figs. 2-4) showing that Trp residues in 
the ZM241385-bound state are in a less polar, less solvent-exposed and potentially 
more sterically-hindered, environment. 
 
3.6. Analysis of Trp-mutated A2AR constructs 
 
Individual Trp residues in the A2AR were mutated to Tyr in an attempt to deconvolute 
the contributions made to the overall fluorescence spectrum by at least some of the 
Trp residues. Trp2466.48 and Trp2687.33 were selected for Tyr substitution as it was 
reasoned that they were most likely to report on A2AR conformational changes, as TM6 
and TM7 are dynamic helices in GPCRs generally and are linked to GPCR activation 
[8]. Both [W246Y]A2AR and [W268Y]A2AR were well-expressed, although the affinity 
for ZM241385 for these mutant receptors was reduced by 6-fold and 27-fold, 
respectively ([W246Y]A2AR - pIC50 6.99 ± 0.46; [W268Y]A2AR - pIC50 6.36 ± 0.17; wild-
type A2AR  pIC50 7.79 ± 0.14). This was not unexpected as Trp2466.48 forms part of the 
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binding site for ZM241385 [33] and Trp2687.33 may influence the local conformation at 
the extracellular face of TM7/ECL3, controlling ligand access to the binding pocket. 
Despite this, it was still possible to measure changes in the fluorescence spectrum 
caused by ZM241385 binding to the mutant constructs, suggesting that the overall 
structure of the protein was maintained. This was further supported by computational 
molecular modelling which revealed that the predicted structures of [W246Y]A2AR and 
[W268Y]A2AR were virtually superimposable on that of WT A2AR, with RMS deviations 
of less than 0.01A (Supplementary Fig 2), suggesting that there was no gross 
disruption of folding. 
In the absence of ZM241385, the spectrum of [W246Y]A2AR-SMALP showed 
two clear peaks, one at 329 nm (like the WT A2AR-SMALP) and a second at 315 nm 
(Fig. 5). Given that the protein can still bind ZM241385, the appearance of this second 
peak is likely to result from the removal of the fluorescence from Trp2466.48, probably 
centred close to 320 nm, which would obscure the fluorescence at 315 nm in the WT 
A2AR. The spectrum of [W268Y]A2AR  in the absence of ZM241385 also showed two 
peaks, again one at 329 nm (like the WT) plus a second peak at 315 nm (Fig 5). The 
relative intensities are different to those observed for [W246Y]A2AR-SMALP but again 
these data are indicative of the mutated Trp having an emission between 315-329 nm.  
Addition of ZM241385 to both mutant receptors led to a significant decrease in 
fluorescence and accompanying red shift (Fig 5). The red shift agreed with that seen 
in the WT A2AR, however the intensity change is completely different (although a red 
shift is more usually seen with an intensity decrease). This suggested that the 
substituted Trp residues contributed an increase in fluorescence upon ZM241385 
binding to the WT A2AR. Their substitution means that these fluorescence decreases 
were caused by one or more of the remaining Trp residues moving to a more polar 
environment in response to ZM241385 binding. The corollary of this, is that both 
Trp2466.48 and Trp2687.33 moved into a less polar environment upon binding 
ZM241385. 
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Fig. 5. Effect of substitution of individual Trp residues on A2AR-SMALP fluorescence. 
Panel a; A2AR-SMALP and [W246Y]A2AR-SMALP in the absence of ZM241385. Panel 
b; A2AR-SMALP and [W268Y]A2AR-SMALP in the absence of ZM241385. Panel c; 
A2AR-SMALP and [W246Y]A2AR-SMALP with ZM241385 (1 M) bound. Panel d; 
A2AR-SMALP and [W268Y]A2AR-SMALP with ZM241385 (1 M) bound.  
 
  
3.7. Analysis of IAEDANS-labelled A2AR 
 
To investigate ligand-induced conformational changes in the cytoplasmic face of the 
A2AR, a fluorescent reporter (IAEDANS) was introduced at residue 6.33, located at the 
cytoplasmic end of TM6. A fluorescent moiety at this locus within the receptor 
architecture is well-placed to report on the dynamic changes that are known to occur 
at the intracellular face of the helical bundle during receptor activation. In particular, 
the large outward movement of the cytoplasmic end of TM6 away from the helical 
bundle that creates the binding crevice in the receptor for G-protein docking [8]. The 
IAEDANS reagent used the current study reacted with thiol groups, so the strategy 
employed involved introducing a Cys at residue 2316.33 followed by derivatisation of 
the A231C mutant construct by IAEDANS. The A2AR used in this study contained 
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fourteen Cys residues (Supplementary Fig. 1b), so it might be assumed that this would 
prevent such a strategy. However, upon closer examination, it can be seen that the 
eight Cys residues in the extracellular loops contribute to disulphide bonds (Cys712.69 
- Cys1595.20; Cys743.22 - Cys1464.67; Cys773.25 - Cys1665.27 and Cys2596.61 - 
Cys2626.64) so will not react with IAEDANS. The remaining six Cys residues (Cys281.54; 
Cys823.30; Cys1284.49; Cys1855.46; Cys2456.47; Cys2546.56) are located in the TMs 
(Supplementary Fig. 1b), so are buried to varying degrees and therefore would be only 
poorly accessible to the IAEDANS. This was confirmed in control experiments that 
established the fluorescence of the WT A2AR-SMALP (with Ala2316.33) after IAEDANS 
labelling was identical to that of ‘empty SMALP’ formed of lipid only and devoid of any 
A2AR (Supplementary Fig. 2). Mutation of A2316.33 did not alter the binding capability 
of the receptor (Supplementary Fig. 3) and following IAEDANS-labelling of Cys2316.33, 
a robust fluorescent signal was detected (Fig. 6). The effect of ligand binding on the 
fluorescence intensity of the IAEDANS-labelled A2AR-SMALP was investigated. 
Binding of the inverse agonist ZM241385 to A2AR-SMALP generated a marked dose-
dependent increase in fluorescence (Fig, 6a) with a pEC50 of 8.74 ± 0.32 (n=3), 
indicating that ZM241385 binding drove the IAEDANS to move to a more hydrophobic 
environment. In contrast, the agonist NECA produced only a 9% increase in 
fluorescence (Fig. 6b) that was nevertheless dose-dependent (Fig. 6c) with a pEC50 
of 6.37 ± 0.21 (n=3).  
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Fig. 6. Ligand-induced changes in IAEDANS fluorescence. 
The effect on fluorescence intensity of exposure to ZM241385 (10-10 M – 10-5 M; panel 
a) or NECA (10-7 M – 10-5 M; panel b) at the concentrations indicated was determined 
for A2AR-SMALP labelled with IAEDANS at residue-231. Panel c; Concentration-
response curves for the fluorescence intensity changes induced by ZM241385 or 
NECA. 
 
 
3.8. Analysis of lipid composition 
 
To confirm that the use of SMALPs for membrane protein extraction allows the local 
lipid environment to be retained, LC-MS/MS was used to characterize the A2AR-
associated phospholipids extracted from P. pastoris membranes using SMALPs, in 
comparison with the total membrane phospholipids (Fig. 7). The phospholipid species 
in SMALP extracts were identified based on the accurate mass and in some cases 
additionally their fragmentation pattern, and are listed in Table 1. The phospholipid 
elution profile on the HILIC column was determined by running standard mixtures of 
phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylcholine 
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(PC), which allowed these lipid classes to be identified in chromatograms of total 
membrane and SMALP extracts (Fig. 7a and Fig. 7b, respectively). Although the 
amount of phospholipid extracted using SMALPs was, not surprisingly, significantly 
less than that obtained from total cell extracts, PE and PC could clearly be identified 
(Fig. 7c and Fig. 7d; Fig. 7g and Fig. 7h). The levels of PS were low even in total 
membrane extracts, and in SMALP extracts they were essentially below the limit of 
detection (Fig. 7e and Fig. 7f). As the phospholipid levels in SMALP extracts were low, 
signals from background contaminant ions in the clusters centred on m/z 758.2, 772.3 
and 829.5 are prominent, especially in Fig. 7f. Overall, whilst there was some evidence 
that the ratio of poly-unsaturated to mono-unsaturated PC species was slightly higher 
in SMALP extracts (e.g. m/z 758.5 vs 760.5, m/z 786.5 vs 788.5 and higher relative 
intensity of m/z 808.5), the profile of SMALP-extracted A2AR-associated phospholipid 
appeared to be generally similar to the total membrane.  
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Figure 7. Comparison of the phospholipid profiles of bulk membrane lipids, and 
SMALP-extracted lipids, from P. pastoris.  
Different classes of phospholipids were separated by HILIC and analysed by 
electrospray MS in positive ion mode. Data were summed across each of the elution 
regions in the TICs shown in panels a and b to generate the spectra for each class 
shown in the panels c-h. The y-axis shows the % intensity in counts per second (cps) 
normalized to 100% for the most intense peak in the spectrum across the mass range 
analysed. For each class of phospholipid, the y-axes of the bulk membrane and 
SMALP spectra are linked to allow a relative comparison of intensity. Note that 
phospholipid signals give m/z values with decimal .5 and signals with m/z values 
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ending .2 or .3 are background contaminants.  Identifications of the individual 
phospholipids are given in Table 1. 
 
Experimental 
m/z  
Retention 
time (min) 
Molecular 
Formula 
Calculated 
m/z 
Error  
in ppm 
Phospholipid 
species 
Glycerophosphocholines ([MH]+) 
732.5528 19.36 C40H79NO8P 732.5543  2.1  GPC (32:1)  
744.5530 19.27 C41H79NO8P 744.5543 1.8  GPC (16:1/17:1)*  
746.5673 19.31 C41H81NO8P 746.5700  3.6  GPC (33:1)  
754.5373 19.27 C42H77NO8P 754.5387 1.8 GPC (34:4) 
756.5529 19.24 C42H79NO8P 756.5543  1.9  GPC (34:3) 
758.5667 19.25 C42H81NO8P 758.5694  3.7  GPC (16:1/18:1)* 
760.5828 19.27 C42H83NO8P 760.5851  3.7  GPC (34:1) 
768.5510 19.22 C43H79NO8P 768.5538  3.6  GPC (18:3/17:1)*  
770.5667 19.20 C43H81NO8P 770.5694  3.5  GPC (35:3) 
772.5844 19.20 C43H83NO8P 772.5851  1.6  GPC (18:1/17:1)* 
780.5526 19.22 C44H79NO8P 780.5538 2.2 GPC (18:3/18:2)* 
782.5667 19.18 C44H81NO8P 782.5695  3.6  GPC (18:2/18:2)* 
784.5823 19.14 C44H83NO8P 784.5851 3.3 GPC (36:3) 
786.5979 19.14 C44H85NO8P 786.6008 3.7 GPC (18:1/18:1)* 
Glycerophosphoethanolamines ([MH]+) 
690.5063 12.43 C37H73NO8P 690.5074  1.6 GPE 32:1) 
704.5217 12.54 C38H75NO8P 704.5230  1.9  GPE (33:1) 
716.5220 12.73 C39H75NO8P 716.5230  1.4  GPE (34:2) 
718.5370 12.68 C39H75NO8P 718.5387  2.3  GPE (34:1) 
738.5059 12.47 C41H73NO8P 738.5074  2.0 GPE (36:5) 
742.5369 12.67 C41H77NO8P 742.5387  2.4  GPE (36:3) 
744.5528 12.70 C41H79NO8P 744.5543  2.1  GPE (18:0/18:2)* 
764.5201 12.65 C43H75NO8P 764.5230  3.8  GPE (38:6) 
766.5348 12.65 C43H77NO8P 766.5387  5.1  GPE (38:5) 
Glycerophosphoserines ([MH]+) 
762.526 14.12 C40H77NO10P 762.5285  3.3  GPS (34:1)  
* Fatty acyl chain composition determined by observation of fatty acyl ions in MS/MS spectra.  
For other phospholipid species the total fatty acyl chain length: double bonds are given. 
 
Table 1. Phospholipid species detected by high resolution LC-MS/MS in SMALP-
extracted P. pastoris samples.  
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4. Discussion 
 
To fully understand the structure and function of a membrane protein it is 
necessary to extract it from the lipid bilayer for purification. This usually requires 
detergents to disrupt the membrane but generally leads to protein instability as the 
lipids of the bilayer are stripped away [34]. In recent years there has been a large 
increase in the use of SMA to extract a wide range of membrane proteins encapsulated 
in SMALPs. This preserves the native membrane environment of the protein albeit on 
a nanoscale, and improves stability. We established previously that the A2AR could be 
purified encapsulated in a SMALP with retention of wild-type ligand binding capability 
[18]. It is well-established that GPCRs can form dimers and that heterodimerization 
can modulate GPCR signalling. Such interaction is maintained within a SMALP, as a 
tetrameric (2+2) complex of ghrelin receptor (GHSR) and dopamine receptor (D2R), 
isolated by SMALP-solubilisation of reconstituted lipid vesicles, retained GHSR 
modulation of D2R signalling [35]. The aim of the current study was to investigate the 
conformational changes induced by binding ligands to the A2AR when it is 
encapsulated in a SMALP.  
 We were able to demonstrate that SMALP-encapsulated A2AR contained 
phospholipids typical of the plasma membrane, including PCs and PEs. It has been 
reported previously that interactions of some GPCRs, e.g. neurotensin receptor 1, with 
G-proteins are dependent on a native-like lipid environment containing PEs [36], 
although the β2-adrenergic receptor showed higher activity in the presence of 
phosphatidylglycerols (PGs) than PEs [10]. Other GPCRs have been reported to 
require cholesterol [11,37] and the active state of the A2AR is stabilised by the binding 
of phosphatidylinositol 4,5-bisphosphate [12]. Although the plasma membrane of P. 
pastoris differs from that of mammalian cells, notably in substitution of cholesterol by 
ergosterol, the major classes of phospholipids are similar and the A2AR was 
pharmacologically active. Phosphatidylinositols and inositol ceramides are minor, 
though important, membrane components and in the present study were below the 
detection limit of the method; hence it is not possible to comment on their contribution 
to the activity observed. However, proteins within SMALPs can be exchanged into 
detergent or amphipol [38] or into vesicles of alternative phospholipid composition [39] 
and SMALP phospholipids can also be exchanged [40], which in the future offers 
alternative approaches for improving GPCR activity following isolation in SMALPs.  
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In its native membrane, the A2AR exhibits considerable constitutive activity in 
the absence of agonist, which can account for over 50% of the agonist-stimulated 
activity [23] and this can be reduced by inverse agonists such as ZM241385 [41]. It is 
well-established that activation of GPCRs involves conformational changes that are 
conserved throughout the receptor family [8]. In particular, there is a large (10 - 14Å) 
movement of the cytoplasmic end of TM6 away from the helical bundle that opens a 
cleft in the cytoplasmic face of the receptor for G-protein docking [42]. The fluorescent 
moiety IAEDANS introduced at residue 2316.33, at the cytoplasmic face of TM6, is 
therefore well-placed to report on the dynamic changes that occur on the intracellular 
face of the A2AR during activation. Indeed, a fluorescent reporter located at the 
corresponding locus in the β2-AR (A2716,33) was used previously to monitor activation 
of the β2-AR [43]. 
The IAEDANS data in the current study show that SMALP-solubilised A2AR 
retains substantial elements of the constitutively active conformation of A2AR existing 
in the native membrane environment. Binding of ZM241385 caused a substantial 
dose-dependent increase in fluorescence emission. The simplest explanation of this 
is that the IAEDANS probe moved into a more hydrophobic environment. This is what 
would be expected if the cytoplasmic end of TM6, in the absence of the inverse 
agonist, was part of an open conformation to accommodate binding of Gsα and binding 
of ZM241385 closed the Gsα binding crevice. Such conformational transitions and 
movement of TM6 between active and inactive A2AR are consistent with the 
corresponding crystal structures [44]. Kinetic data indicate that the binding of 
ZM241385 is biphasic, consistent with conformational changes of the receptor [45]. In 
contrast, the agonist NECA caused very little change in IAEDANS fluorescence 
emission. 
 The fluorescence of endogenous Trp residues is a powerful technique to study 
the conformation of native proteins. Trp are important residues in their own right. Their 
large size, coupled with the ability to take part in hydrophobic and columbic 
interactions means that they often act as switches or pivots during conformational 
changes. There are a number of highly conserved Trp residues in GPCRs, including 
Trp6.48 in TM6, referred to as the “rotamer toggle switch” [46]. An agonist-induced shift 
of this conserved Trp6.48 promotes the outward tilt of the intracellular part of TM6 
required for G-protein coupling described above. It has already been noted that 
IAEDANS fluorescence emission was affected by ZM241385 binding and ZM241385 
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also caused changes in the environments of the Trp residues in the SMALP-solubilised 
A2AR. The agonist NECA however, did not affect the Trp fluorescence. The 
predominant change upon ZM241385 binding involved an increase in fluorescence 
emission and the appearance of three distinct peaks in the fluorescence spectrum at 
321 nm, 335 nm and 350 nm. Interestingly, two of these peaks (321 nm, 335 nm) have 
wavelengths that are not far from those observed in the spectra of the unliganded 
mutant constructs [W2466.48Y]A2AR-SMALP and [W2687.33Y]A2AR-SMALP (peaks at 
315 nm and 329 nm). This confirms that in each conformation there are Trp residues 
present that maintain similar spectroscopy. 
Analysis of the Trp/Tyr substitution mutants suggests that Trp2466.48 and 
Trp2687.33 are responsible for the increase in the fluorescence emission observed 
when ZM241385 binds to the WT. These Trp residues are not located near to the 
cytoplasmic face of the A2AR and thus report on different regions from that measured 
by the IAEDANS at residue 2316.33. For Trp2466.48 in TM6, two mechanisms may 
contribute to the change in fluorescence. The antagonist may trigger a conformational 
change in the A2AR-SMALP that moves the residue to a more hydrophobic 
environment. However, binding of ZM241385 could also reduce the solvent 
accessibility of Trp2466.48 as it is located in the ZM241385 binding pocket where it 
forms a hydrophobic contact with the furan ring of ZM241385 [33], along with adjacent 
residues [47]. Both mechanisms could decrease the rotation of the residue, consistent 
with the measured reduction in anisotropy and hence fluorophore mobility. However, 
as NECA also binds close to Trp2646.48 and yet does not change Trp fluorescence, it 
seems a conformational change in the receptor is the most likely explanation. 
Our observation that the inverse agonist ZM241385, which inhibits activation, 
caused the ‘rotamer toggle switch’ Trp2466.48 of the A2AR-SMALP to move to a more 
hydrophobic environment is the exact opposite effect to that accompanying photo-
activation of rhodopsin. Photo-activation of rhodopsin causes the corresponding 
residue (Trp2656.48) to transition to a more hydrophilic environment [48]. These two 
observations are consistent with respect to linking the nature of the Trp6.48 environment 
and the activation state of the GPCR. 
Trp2687.33 is at the extracellular face of TM7, on the boundary between the 
membrane and the extracellular aqueous medium. ZM241385 binds in an extended 
conformation perpendicular to the plane of the membrane. Nevertheless, the changes 
seen here are unlikely to be due to direct contact with ZM241385 with Trp2687.33, so 
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probably reflect changes in receptor conformation, although crystal structures reveal 
that ZM241385 does make hydrophobic interactions with other residues at the 
extracellular face of TM7 (L2677.32 and M2707.35) [49,50]. There is also evidence for 
movement of ECL3 during activation of the A2AR with molecular dynamic studies 
suggesting that compaction of the extracellular domain of the A2AR underlies the 
positive allosteric effects of divalent cations as they bridge across acidic residues in 
ECLs [51]. Even a small movement of the indole head-group of Trp2687.33 towards the 
membrane, induced by ZM241385 binding, would be expected to significantly reduce 
its polarity and could potentially reduce its mobility. Another factor that could be 
relevant to changes in the environment of residues within the TM helical bundle are 
the ordered water molecules within the receptor structure [49,52]. Whilst the changes 
seen with Trp2466.48 and Trp2687.33 dominate the spectrum, their substitution by Tyr 
unmasks changes due to other Trp residues having greater solvent accessibility. 
Caution is needed in interpreting this as the Trp/Tyr mutations have some effect on 
ZM242385 binding. Nevertheless, despite this caveat, it is at least plausible that in the 
WT receptor some of the Trp residues on, or close to, the intracellular or extracellular 
loops will have greater solvent exposure following antagonist binding, thus 
experiencing an increase in polarity. 
 In conclusion, the SMALP-solubilised A2AR adopted a conformation that 
retained the native constitutive activity. Using fluorescence changes from endogenous 
Trp residues and an introduced IAEDANS, we established that the receptor was able 
to undergo ligand-induced conformational changes with the SMALP environment in 
response to binding the inverse agonist ZM241385. In contrast, the SMALP-encapsulated 
A2AR exhibited little conformational change in response to the full agonist NECA. 
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Supplementary Figures. 
 
 
 
Supplementary Fig. 1. Schematic diagram of the A2AR. 
Panel a; Trp residues are shown as grey circles. Panel b; Cys residues are shown as 
coloured circles in the extracellular loops and as grey circles in the TM helices. 
Disulphide bonds are indicated as per the crystal structure (PDB ID: 3EML).  
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Supplementary Fig. 2. Comparison of A2AR structures. 
The structure of WT A2AR bound to ZM241385 (yellow) is aligned with the predicted 
structures of [W246Y]A2AR (red) and [W268Y]A2AR (blue) from computational 
molecular modelling. RMS deviations less than 0.01A. 
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Supplementary Fig. 3. Fluorescent emission spectrum of IAEDANS. 
Panel a; IAEDANS fluorescent emission spectrum of WT A2AR (Ala231). Panel b; 
IAEDANS fluorescent emission spectrum of ‘empty SMALPs’ containing only the lipid 
DMPC. 
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Supplementary Fig. 4. Mutation of Ala2316.33 does not affect ZM241385 binding. 
Binding curves for ZM241385 binding to wild-type () and mutant () A2AR. 
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